Literature DB >> 22929559

Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity?

C T Costiniuk1, J B Angel.   

Abstract

While only partial immune reconstitution in gut-associated lymphoid tissue typically occurs following initiation of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV) infection, near-complete immune reconstitution has occasionally been described. This review highlights findings from studies examining the effects of HAART and the timing of its initiation on gastrointestinal (GI) CD4+ T-cell recovery. Its effects on specific CD4+ T-cell subtypes, CD8+ T cells, natural killer cells, and immunoglobulins are also described. Finally, the ability of HAART to restore the intestinal epithelial barrier and lymphatic tissue architecture and reduce microbial translocation is addressed. Determining whether HAART has the ability to prevent permanent GI immune damage when commenced in acute HIV infection has implications for the optimal timing of HAART initiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929559     DOI: 10.1038/mi.2012.82

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  32 in total

1.  Intestinal CD4 Depletion in HIV / SIV Infection.

Authors:  Ronald S Veazey
Journal:  Curr Immunol Rev       Date:  2019

2.  Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques.

Authors:  Namal P M Liyanage; Shari N Gordon; Melvin N Doster; Poonam Pegu; Monica Vaccari; Nebiyu Shukur; Luca Schifanella; Cynthia A Pise-Masison; Danuta Lipinska; Kamil Grubczak; Marcin Moniuszko; Genoveffa Franchini
Journal:  Virology       Date:  2014-01-21       Impact factor: 3.616

Review 3.  Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Authors:  Paul Kelly; Haroon Saloojee; Jennifer Y Chen; Raymond T Chung
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.

Authors:  Vanessa El Kamari; Carlee Moser; Corrilynn O Hileman; Judith S Currier; Todd T Brown; Liz Johnston; Peter W Hunt; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 5.  Immune and genetic gardening of the intestinal microbiome.

Authors:  Jonathan P Jacobs; Jonathan Braun
Journal:  FEBS Lett       Date:  2014-03-05       Impact factor: 4.124

6.  Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression.

Authors:  Ankita Garg; Pratima Rawat; Stephen A Spector
Journal:  J Infect Dis       Date:  2014-09-18       Impact factor: 5.226

7.  Marked Enteropathy in an Accelerated Macaque Model of AIDS.

Authors:  Joshua D Croteau; Elizabeth L Engle; Suzanne E Queen; Erin N Shirk; M Christine Zink
Journal:  Am J Pathol       Date:  2017-01-03       Impact factor: 4.307

8.  Impact of early cART in the gut during acute HIV infection.

Authors:  Claire Deleage; Alexandra Schuetz; W Gregory Alvord; Leslie Johnston; Xing-Pei Hao; David R Morcock; Rungsun Rerknimitr; James L K Fletcher; Suwanna Puttamaswin; Nittaya Phanuphak; Robin Dewar; Joseph M McCune; Irini Sereti; Merlin Robb; Jerome H Kim; Timothy W Schacker; Peter Hunt; Jeffrey D Lifson; Jintanat Ananworanich; Jacob D Estes
Journal:  JCI Insight       Date:  2016-07-07

Review 9.  Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies.

Authors:  S F Assimakopoulos; D Dimitropoulou; M Marangos; C A Gogos
Journal:  Infection       Date:  2014-07-29       Impact factor: 3.553

10.  Gastrointestinal viral load and enteroendocrine cell number are associated with altered survival in HIV-1 infected individuals.

Authors:  Guido van Marle; Keith A Sharkey; M John Gill; Deirdre L Church
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.